{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:29Z","timestamp":1766514149820,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000200","name":"USAID","doi-asserted-by":"crossref","award":["72061718C00001."],"award-info":[{"award-number":["72061718C00001."]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection constitute a deadly infectious disease synergy disease and major public health problem throughout the world. The risk of developing active TB in people living with HIV (PLHIV) is 21 times higher than the rest of the world population. The overlap of latent TB infection and HIV infection has resulted in marked increases in TB incidence in countries with dual epidemics. Although antiretroviral therapy (ART) is the single most significant way to reduce incident TB in PLHIV, besides early ART initiation, isoniazid preventive therapy (IPT) is the key intervention to prevent TB among PLHIV. This prospective cohort and longitudinal study aimed to document; retention, adherence, development of active TB disease, possible adverse drug reactions and completion among patients initiated on IPT in Jan 2019.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was both a prospective cohort and longitudinal study nested within a national quality improvement collaborative in which multiple quality improvement teams tested changes in care delivery to improve the delivery of IPT. The prospective cohort were HIV patients without TB disease initiated on a dosage of Isoniazid 300\u00a0mg\/day for adults and 150\u00a0mg\/day for children for a period of 6\u00a0months. Association statistics were used to describe patient characteristics and outcomes. Variables with p-value\u2009&lt;\u20090.05 were used to determine linear by linear associations between patient characteristics assumed to influence both primary and secondary outcomes. Variables with a p-value\u2009&lt;\u20090.05 were included in the logistical regression model. The final model included those factors that retained statistical significance. The odds ratios (OR) and adjusted OR (AOR) along with its 95% confidence interval were used to determine the power of relationship in determining the outcomes of interest. The model was tested for fitness using goodness-of-fit Hosmer\u2013Lemeshow tests.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The completion of IPT was at 89%. A significant proportion of patients adhered to treatment (89%) and kept their appointment schedules-retention (89%). All patients (100%) received IPT at each appointment visit. Only 4% of patients experienced side effects of isoniazid (INH) but none of them developed active TB at the end of the 6\u00a0month INH dose. Multivariate logistic regression analysis of covariates of IPT completion revealed a strong and statistical association between IPT completion and age, gender, retention and side effects of INH. Our multivariate model found that children below 15\u00a0years were less likely to complete INH than patients\u2009\u2265\u200915\u00a0years (<jats:italic>AOR\u2009<\/jats:italic>=\u20090.416, <jats:italic>p\u2009<\/jats:italic>=\u20090.230, <jats:italic>df\u2009<\/jats:italic>=\u20091). Female patients were 2 times more likely to complete INH dose than male patients (AOR\u2009=\u20091.598, <jats:italic>p\u2009<\/jats:italic>=\u20090.018). Patients who kept all their appointment schedules were 10 times more likely to complete IPT than those who missed one or more schedules (<jats:italic>AOR\u2009<\/jats:italic>=\u200910.726, <jats:italic>p\u2009<\/jats:italic>=\u20090.000, <jats:italic>df\u2009<\/jats:italic>=\u20091). We also found that patients who did not report any side effects associated with INH were 2 times more likely to complete INH (<jats:italic>AOR\u2009<\/jats:italic>=\u20091.958, <jats:italic>p\u2009<\/jats:italic>=\u20090.016, <jats:italic>df\u2009<\/jats:italic>=\u20091) than patients who reported one or more side effects.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Treatment completion is the end-point of the IPT initiation strategy in Uganda. With a completion rate of 89%, our results seem re-assuring and suggest that improvement collaborative is an effective approach to achieving results through combined efforts. The high rates of completion are encouraging indicators of progress in the implementation of collaborative activities in the study setting. However, such collaboratives would require periodic evaluation to prevent possible relapses in progress attained.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12981-020-00285-0","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T12:03:00Z","timestamp":1590580980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda"],"prefix":"10.1186","volume":"17","author":[{"given":"Simon","family":"Sensalire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Karungi Karamagi Nkolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Nabwire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lawino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dithan","family":"Kiragga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Muhire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Kadama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cordelia","family":"Katureebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Proscovia","family":"Namuwenge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Musinguzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Calnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejene","family":"Seyoum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"285_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4084\/mjhid.2014.070","volume":"6","author":"G Sulis","year":"2014","unstructured":"Sulis G, Roggi A, Matteelli A, Raviglione MC. Tuberculosis: epidemiology and control. Mediterr J Hematol Infect Dis. 2014;6:1.","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"285_CR2","unstructured":"World Health Organization. Global tuberculosis control. WHO report 2017. https:\/\/www.who.int\/tb\/publications\/global_report\/gtbr2017. Accessed 2 Aug 2017."},{"key":"285_CR3","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","volume":"163","author":"EL Corbett","year":"2013","unstructured":"Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2013;163:1009\u201321.","journal-title":"Arch Intern Med"},{"key":"285_CR4","unstructured":"World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: WHO; 2015 (http:\/\/www.who.int\/tb\/publications\/ltbidocument_page\/en\/. Accessed 30 Aug 2016."},{"key":"285_CR5","unstructured":"National Policy and Guidelines for TB\/HIV Collaborative Activities in Uganda. Ministry of Health, Uganda. https:\/\/www.who.int\/hiv\/pub\/guidelines\/uganda.pdf. Accessed 14 Oct 2016."},{"issue":"Suppl 2","key":"285_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s11606-006-0267-9","volume":"21","author":"CB Stetler","year":"2006","unstructured":"Stetler CB, Legro MW, Wallace CM, Bowman C, Guihan M, Hage-dorn H, Kimmel B, Sharp ND, Smith JL. The role of formative evaluation in implementation research and the QUERI experience. J Gen Intern Med. 2006;21(Suppl 2):S1\u20138.","journal-title":"J Gen Intern Med"},{"key":"285_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/230587","volume":"2014","author":"M Berhe","year":"2014","unstructured":"Berhe M, Demissie M, Tesfaye G. Isoniazid preventive therapy adherence and associated factors among HIV positive patients in Addis Ababa. Ethiopia Adv Epidemiol. 2014;2014:1\u20136.","journal-title":"Ethiopia Adv Epidemiol."},{"key":"285_CR8","first-page":"5","volume":"76","author":"KH Tram","year":"2017","unstructured":"Tram KH, Mwangwa F, Atukunda M, Owaraganise A, Ayieko J, Plenty A, Kwariisima D, Clark TD, Petersen ML, Charlebois ED, Kamya MR, Chamie G, Havlir DV, Marquez C. search collaboration isoniazid preventive therapy completion in the era of differentiated HIV care. PMJ Acquir Immune Defic Syndr. 2017;76:5.","journal-title":"PMJ Acquir Immune Defic Syndr."},{"key":"285_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/QAD.0000000000000831","volume":"29","author":"M Yotebieng","year":"2015","unstructured":"Yotebieng M, Edmonds A, Lelo A, Wenzi LK, Ndjibu PT, Lusiama J, Kabuayi JP, Behets F. High completion of Isoniazid Preventive Therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo. AIDS. 2015;29:15.","journal-title":"AIDS."},{"issue":"9","key":"285_CR10","first-page":"1037","volume":"12","author":"PJ Munseri","year":"2008","unstructured":"Munseri PJ, Talbot EA, Mtei L, Fordham von Reyn C. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis. 2008;12(9):1037\u201341.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"Suppl 5","key":"285_CR11","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/01.aids.0000391022.95412.a6","volume":"24","author":"B Durovni","year":"2010","unstructured":"Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, Cohn S, Efron A, Pacheco AG, Moulton LH, Chaisson RE, Golub JE. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB\/HIV in Rio (THRio) study. AIDS. 2010;24(Suppl 5):S49\u201356.","journal-title":"AIDS."},{"issue":"9","key":"285_CR12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1473-3099(15)00147-4","volume":"15","author":"A Nanoo","year":"2015","unstructured":"Nanoo A, Izu A, Ismail NA, Ihekweazu C, Abubakar I, Mametja D, et al. Nationwide and regional incidence of microbiologically confirmed pulmonary tuberculosis in South Africa, 2004\u201312: a time series analysis. Lancet Infect Dis. 2015;15(9):1066\u201376.","journal-title":"Lancet Infect Dis."},{"issue":"11","key":"285_CR13","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1097\/QAD.0b013e32833a097b","volume":"24","author":"Z El-Khatib","year":"2010","unstructured":"El-Khatib Z, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010;24(11):1679\u201387.","journal-title":"AIDS."},{"issue":"6","key":"285_CR14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.5588\/ijtld.10.0284","volume":"15","author":"JJ Van der Watt","year":"2011","unstructured":"Van der Watt JJ, Harrison TB, Benatar M, Heckmann JM. Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV\/AIDS era: a systematic review. Int J Tuberc Lung Dis. 2011;15(6):722\u20138.","journal-title":"Int J Tuberc Lung Dis."},{"key":"285_CR15","first-page":"6","volume":"1","author":"Ashley Wynne","year":"2014","unstructured":"Wynne Ashley, Richter Solina, Banura Lilian, Kipp Walter. Challenges in tuberculosis care in Western Uganda: health care worker and patient perspectives International. J Afr Nurs Sci. 2014;1:6\u201310.","journal-title":"J Afr Nurs Sci"},{"issue":"8","key":"285_CR16","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/heapol\/czx057","volume":"32","author":"L Bam","year":"2017","unstructured":"Bam L, McLaren ZM, Coetzee E, Von Leipzig KH. Reducing stock-outs of essential tuberculosis medicines: a system dynamics modelling approach to supply chain management. Health Policy Plann. 2017;32(8):1127\u201334.","journal-title":"Health Policy Plann"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-020-00285-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T23:45:29Z","timestamp":1622072729000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-020-00285-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1186\/s12981-020-00285-0","relation":{},"ISSN":["1742-6405"],"issn-type":[{"type":"electronic","value":"1742-6405"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"27 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocols used in this study were reviewed and approved by the institutional review board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}